PGx-guided antidepressants modestly increase short-term response and remission in MDDGenetic testing may help patients find the right antidepressant

Journal of psychiatric research Published October 1, 2026 Study authors: Pullano Ilaria, Iazzolino Anna Maria, Di Lorenzo Chiara, Monaco Francesco, Miola Alessandro, Fornaro… PubMed ↗ DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret PGx-guided antidepressant results cautiously given heterogeneity and few trials.

This meta-analysis evaluated pharmacogenomic (PGx)-guided antidepressant treatment compared with treatment as usual or unguided care in adults with major depressive disorder, focusing on response and remission during an 8 to 12 week acute window.

In the GeneSight analysis, PGx-guided care was associated with increased response (RR 1.30, 95% CI 1.09 to 1.56) and increased remission (RR 1.53, 95% CI 1.19 to 1.97).

The cross-platform analysis showed heterogeneous and imprecise results for both response (RR 1.18, 95% CI 0.91 to 1.54; I = 78%) and remission (RR 1.18, 95% CI 0.77 to 1.80; I = 82%).

Limitations noted by the authors include a small number of short-term randomized controlled trials, residual risk-of-bias concerns, and heterogeneity or imprecision in the secondary exploratory cross-platform analysis. Safety outcomes, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Funding and conflicts of interest were not reported.

The authors caution that these findings are not evidence of superiority of one commercial PGx platform over others. The association between GeneSight-guided care and modest short-term increases in response and remission should be interpreted in the context of these limitations.

How this fits prior evidence

This meta-analysis extends prior coverage of antidepressant safety and treatment response prediction in MDD. It aligns with the prior finding that lower baseline IL-2 and IL-6 levels may signal antidepressant response, adding pharmacogenomic-guided care as another potential predictor of short-term response and remission. It contrasts with the prior observation that antidepressant use is associated with a 1.34 increased risk of ventricular arrhythmia and sudden cardiac death, as safety outcomes were not reported here. The modest and heterogeneous cross-platform results also contrast with the more consistent benefit reported for lumateperone 42 mg plus ADT in MDD with anxious distress.

Finding the right medication for major depressive disorder can be a long and frustrating process of trial and error. New data suggests that using a specific genetic test, called GeneSight, might help doctors choose the right antidepressant more effectively during the initial treatment window.

In this analysis, patients who received treatment guided by the GeneSight test showed a higher rate of response compared to those receiving standard care. The data also showed an increased rate of remission, which means the symptoms of depression significantly improved. These results were observed over a short period of about 8 to 12 weeks.

While these results are promising, the evidence is still early. The study was based on a small number of short-term trials, and some broader data across different platforms was less precise. It is important to note that this does not mean one genetic testing brand is better than another, but rather that guided care showed some benefit in this specific study.

What this means for you:

Genetic testing may improve the chances of finding an effective antidepressant during the first few months of treatment.

Common questions

How does genetic testing help with depression?

Genetic testing, or pharmacogenomics, looks at how your genes might affect your body's response to certain medications. In this study, using a specific test called GeneSight helped patients find an antidepressant that worked for them more effectively during the first 8 to 12 weeks of treatment.

Is this a proven way to treat depression?

The study showed a higher rate of response and remission for those using the GeneSight test. However, the evidence comes from a small number of short-term trials. Because the data is still limited, you should talk to your doctor about how this might apply to your specific treatment plan.

What are the limitations of this finding?

The results for the GeneSight test were positive, but other broader tests across different platforms were less precise and varied. The study also notes that there is not enough evidence to say one specific genetic testing brand is better than another.

Study Details

Study typeMeta analysis

EvidenceLevel 1

Follow-up2.8 mo

PublishedOct 2026

PMID42462453

View Original Abstract ↓

BACKGROUND: Combinatorial pharmacogenomic (PGx) tests aim to guide antidepressant selection and dosing in adult major depressive disorder (MDD), but available platforms differ in gene content, decision rules, clinical reporting, and implementation. Therefore, indiscriminate pooling across PGx platforms may obscure platform-specific effects. METHODS: We searched MEDLINE (PubMed), Embase, and APA PsycINFO from inception to 31 December 2025, screened reference lists, and conducted a formal update search on 14 April 2026 using the same search concepts and eligibility criteria. We included RCTs enrolling adults with MDD and comparing PGx-guided antidepressant prescribing versus treatment as usual (TAU)/unguided care. Two RCT-only quantitative syntheses were prespecified: (a) a primary platform-specific analysis restricted to GeneSight RCTs and (b) a secondary exploratory cross-platform analysis of other multigene PGx panels. Random-effects models were used; effects are reported as risk ratios (RRs). RESULTS: Eight RCTs were included. In the primary platform-specific GeneSight analysis (three trials), PGx-guided care increased response (RR 1.30, 95% CI 1.09-1.56; I = 0%) and remission (RR 1.53, 95% CI 1.19-1.97; I = 0%) within the prespecified 8-12-week acute window. In the secondary exploratory cross-platform analysis (five trials for response; four for remission), effects were heterogeneous and imprecise: response RR 1.18 (95% CI 0.91-1.54; I = 78%) and remission RR 1.18 (95% CI 0.77-1.80; I = 82%). CONCLUSIONS: In adult MDD, GeneSight-guided care was associated with modest short-term increases in response and remission within the available RCT evidence. Pooled effects across other multigene PGx panels were heterogeneous and imprecise. The platform-aware structure reflects differences in data availability, comparability, and internal validity, and it should not be interpreted as evidence of superiority of one commercial PGx platform over others. Evidence was limited by the small number of short-term RCTs, residual risk-of-bias concerns, and heterogeneity/imprecision in the secondary exploratory cross-platform analysis. Future trials should harmonize outcomes, follow-up, implementation reporting, and platform-specific decision-support descriptions to improve cross-platform comparability.

PGx-guided antidepressants modestly increase short-term response and remission in MDDGenetic testing may help patients find the right antidepressant

How this fits prior evidence

Common questions

Study Details

PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder

The Algorithm That Helps Doctors Pick the Right Antidepressant for You

Clinical research that matters. Delivered to your inbox.

PGx-guided antidepressants modestly increase short-term response and remission in MDDGenetic testing may help patients find the right antidepressant

How this fits prior evidence

Common questions

More on Major Depressive Disorder

Study Details

PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder

The Algorithm That Helps Doctors Pick the Right Antidepressant for You

Clinical research that matters. Delivered to your inbox.

Related in Psychiatry

From Other Specialties